DiaMedica (DMAC) Q1 2026 earnings review
Pivotal Catalysts Creep Further Out as Cash Burn Accelerates
DiaMedica is a pre-revenue biotech advancing its lead asset, DM199, for stroke and preeclampsia. Q1 2026 results show a classic clinical-stage squeeze: costs are rising while key data timelines slip. R&D spending accelerated to $8.0M, pushing the net loss to $10.0M. Management notes that the ReMEDy2 stroke trial has surpassed 70% enrollment, but the critical interim analysis has drifted again—now slated for Q4 2026. A U.S. clinical hold on the preeclampsia program also remains unresolved. With $51.3M in cash, the company projects a runway through 2027, but continuous execution delays are weighing on the narrative.
🐂 Bull Case
DiaMedica expects four separate preeclampsia data readouts and one fetal growth restriction (FGR) readout by the end of 2027. The next major catalyst is the Phase 2 Part 1a dataset expected in 2Q 2026.
With $51.3M in cash and short-term investments, DiaMedica remains funded through 2027, bridging the gap to the critical ReMEDy2 stroke trial interim analysis without immediate dilution risk.
🐻 Bear Case
The ReMEDy2 interim analysis was originally guided for H1 2026, then pushed to H2 2026, and is now explicitly delayed to 4Q 2026, eroding confidence in the company's clinical execution.
The U.S. Phase 2 preeclampsia trial remains stalled. The FDA rejected the rabbit toxicity model, and DiaMedica is still waiting on FDA alignment for a second rodent model, indefinitely delaying U.S. clinical progress.
⚖️ Verdict: 🔴
Bearish. While the balance sheet is secure for now, the escalating cost of operations ($10.0M net loss) paired with delayed inflection points creates a tough setup. Clinical-stage biotechs are valued on catalyst execution, and DiaMedica's timelines continue to drift to the right.
Key Themes
Upcoming DM199 Preeclampsia Data
The Phase 2 Investigator-Sponsored Trial (IST) in preeclampsia is progressing, with the Part 1a dose-escalation extension cohort (12 participants) fully enrolling. A dataset readout is anticipated in 2Q 2026. This data will be critical in validating the therapeutic dose for the upcoming Phase 3 program and proving DM199's efficacy.
Global Preeclampsia Expansion
To bypass the U.S. FDA bottleneck, DiaMedica is aggressively shifting clinical operations to other jurisdictions. Health Canada has approved site selections with the first patient expected to be dosed before the end of 2026. Additionally, a clinical trial application (CTA) to expand into the U.K. is planned for 2Q 2026.
ReMEDy2 Stroke Trial Reaching Critical Mass
The Phase 2/3 ReMEDy2 trial for Acute Ischemic Stroke (AIS) has finally surpassed the 70% enrollment threshold required for its interim analysis. This milestone is a prerequisite for the independent Data Safety Monitoring Board to review the first 200 patients, which will dictate if the trial succeeds, fails, or requires up to 728 patients.
ReMEDy2 Timeline Slippage Contradicts 'Momentum'
Despite management celebrating that 70% enrollment has been reached, the guidance for the interim analysis has been pushed to 4Q 2026. In early 2025, this was guided for H1 2026, and late last year it was guided for H2 2026. This specific delay contradicts management's prior commentary about 'encouraging enrollment momentum' and signals persistent recruitment friction.
U.S. FDA Roadblock for Preeclampsia
The U.S. IND for early-onset preeclampsia remains effectively on hold. Preliminary results showed rabbits developed an antibody response to DM199, ruining the embryo-fetal development study required by the FDA. The company has proposed a second rodent model but is still awaiting the FDA's response, leaving the U.S. clinical timeline completely opaque.
Accelerating Cash Burn
Clinical expansion is taking a severe toll on the income statement. R&D expenses accelerated to $8.0M in Q1 2026, a 40% increase YoY from $5.7M. Net cash used in operating activities increased from $7.1M to $9.1M. Management explicitly stated they expect R&D expenses to 'moderately increase in future periods,' which will further pressure the cash runway.
Macro: Hospital Staffing Constraints Hindering Execution
Management continues to cite 'hospital and medical facility staffing shortages' as a direct risk factor for their operations. Given the continual delays in the ReMEDy2 stroke trial enrollment, it is evident that systemic macro-level healthcare staffing constraints are actively impeding the company's ability to execute complex, time-sensitive clinical trials in acute care settings.
Other KPIs
Decelerating. Cash reserves fell from $59.9 million at the end of 2025. While this represents a healthy liquidity cushion for a company of this size, the $8.6M quarter-over-quarter drop illustrates the accelerating cost of maintaining concurrent global clinical trials.
Accelerating. Up 28% from $7.1 million in the same quarter last year. The widening operating deficit is the direct result of expanding the ReMEDy2 trial footprint and conducting additional reproductive toxicity testing to appease U.S. regulators.
Guidance
Decelerating. This is a noticeable delay from previous 'second half of 2026' and earlier 'first half of 2026' estimates, indicating persistent patient recruitment challenges for the acute stroke study.
Stable. Despite rising R&D costs, management maintains that current reserves will fund operations and planned studies through 2027. This provides roughly 6-7 quarters of breathing room before a dilutive capital raise becomes mandatory.
Stable. The 12-participant dose-escalation extension cohort is on track to deliver an updated dataset in the current quarter, representing the most immediate catalyst for the stock.
Key Questions
FDA Alignment on Toxicity Model
What is the specific timeline to hear back from the FDA regarding the alternative rodent model for the reproductive toxicity study, and what is the contingency plan if the FDA requires further novel animal testing?
ReMEDy2 Enrollment Reality
You noted that ReMEDy2 has surpassed 70% enrollment, yet the interim analysis is pushed to 4Q 2026. What is the actual mathematical enrollment rate (patients per site per month) you are currently observing, and what is causing the prolonged tail of recruitment?
Cash Runway vs. ReMEDy2 Expansion
Your guidance projects cash through 2027 based on 'planned clinical studies.' If the ReMEDy2 interim analysis in 4Q 2026 mandates upsizing the trial to the maximum 728 patients, does your current cash balance still fund operations through 2027?